Systemic Lupus Erythematosus

HUTCHMED Completes Rolling Submission of NDA to FDA for Fruquintinib HUTCHMED (China) Limited announced the completion of the rolling submission of a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1,...

Lupus Nephritis (LN) is the most feared and common complication of systemic lupus erythematosus (SLE) and is responsible for the major share of morbidity and mortality of this disease. It affects around half of the systemic lupus erythematosus patients, and in ~35% of patients, lupus nephritis is the presenting fea...

Pfizer and Lilly's JAK Inhibitors Safety Concerns Prompt Europe to Investigate the Drug Class The risk of heart problems associated with the use of JAK inhibitors has called the entire drug class into question. In September, the FDA announced that it would require safety warnings for drugs such as Pfizer's Xelja...

Systemic Lupus Erythematosus is a chronic inflammatory disease that affects connective tissues such as cartilage and blood vessel lining, which provide strength and flexibility to body structures. Systemic Lupus Erythematosus affects multiple organs and structures, including the skin, joints, kidneys, lungs, centra...

Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder therapy into the clinic with a USD 30 million upfront rights agreement. Aelis, clinical-stage French biotech zeroed in on brain disorders...

Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the...

Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...

Amid the political debate, the US NIH has last week begun the clinical trials of the malarial drug hydroxychloroquine to test its efficacy and safety in patients with COVID-19. What is hydroxychloroquine?  Hydroxychloroquine (HCQ) (aka hydroxychloroquine sulfate), is a drug available in the market to tre...

Systemic Lupus Erythematosus (SLE) is a chronic, multisystem, inflammatory autoimmune disease which leads to weakening of the immune system. It results in systemic inflammation which affects multiple organs such as kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain. Acute Cutaneous Lupus, ...

Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease. The disease has a highly variable course and prognosis. The term lupus has been used to identify a number of chronic, autoimmune diseases that can damage any part of the body (such as skin, joints, and/or organs inside the body). Common symptoms in...